Welcome to our dedicated page for Zai Lab American Depositary Shares news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab American Depositary Shares stock.
Zai Lab Limited (NASDAQ: ZLAB) is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines. Established in 2013 by industry veterans, Zai Lab addresses some of the world's most pressing unmet medical needs with a vision to transform patients’ lives globally.
The company employs a dual approach of in-licensing products and internal research and development to maintain a robust pipeline. This strategy has led to the development of promising drug candidates aimed at treating a range of severe health conditions, particularly in oncology, autoimmune, and infectious diseases.
Core Products and Pipeline:
- ZL-2306: An investigational treatment for multiple solid tumor types, including ovarian, breast, and lung cancers.
- ZL-2401: A novel antibiotic belonging to a new class of tetracycline derivatives, significant in the battle against resistant bacterial infections.
- ZL-2301: An oral small molecule targeting hepatocellular carcinoma (HCC), promising for liver cancer treatment.
Zai Lab's leadership team is acclaimed for their innovative regulatory approval pathways in China, which have expedited the introduction of new therapies. The company's partnerships with global pharmaceutical giants underscore its commitment to conducting world-class clinical development both in China and internationally.
Financially, Zai Lab has strong support from a cadre of leading healthcare investors, ensuring robust backing for its ambitious projects. This financial stability allows the company to explore cutting-edge research and expand its therapeutic offerings continually.
Recent Achievements and Current Projects:
- Successful initiation of multiple late-stage clinical trials across various therapeutic areas.
- Establishment of strategic partnerships with multinational pharmaceutical companies to enhance drug development and commercialization.
- Ongoing expansion of their research facilities to accommodate new projects and collaborations.
Zai Lab remains committed to leveraging its expertise, innovation, and strategic partnerships to bring life-changing therapies to market, ultimately improving patient outcomes worldwide.
Schrödinger and Zai Lab have entered a global collaboration in precision oncology, focusing on a novel program targeting DNA damage response. This partnership aims to leverage Schrödinger's computational platform for drug discovery, with Zai Lab providing commercialization expertise. Under the agreement, Zai Lab will make an upfront payment to support research costs and will lead global development after selecting a candidate. Schrödinger could receive up to $338 million in milestone payments and royalties on global sales, enhancing its pipeline and potential market position.
Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) plans to report its financial results for Q2 2021 on August 9, 2021, after U.S. market close. A live conference call and webcast will occur on August 10, 2021, at 8:00 a.m. EDT. The company specializes in developing therapies for oncology, autoimmune disorders, and infectious diseases. With a solid pipeline and partnerships with leading biopharmaceutical companies, Zai Lab is focused on addressing unmet medical needs globally.
Zai Lab has entered a collaboration agreement with MacroGenics, acquiring rights for up to four bispecific molecules targeting cancer. Zai will commercialize these in Greater China, Japan, and Korea, while MacroGenics holds rights in other regions. The deal includes an upfront payment of $25 million and a $30 million equity investment in MacroGenics. Zai may convert the regional rights into a global profit share upon achieving clinical milestones. MacroGenics could receive up to $1.4 billion in milestone payments along with royalties on net sales.
Zai Lab has secured the rights to develop and exclusively commercialize adagrasib in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. This collaboration with Mirati Therapeutics involves an upfront payment of $65 million, milestone payments potentially totaling $273 million, and tiered royalties. The agreement aims to accelerate enrollment in global clinical trials for patients with KRASG12C mutations, targeting multiple cancer types including lung and colorectal cancers.
Mirati Therapeutics and Zai Lab have entered a collaboration to develop and commercialize adagrasib, a KRASG12C inhibitor, in Greater China. Zai Lab secures rights for research, development, and commercialization, facilitating accelerated enrollment in pivotal clinical trials. Mirati receives a $65 million upfront payment with potential additional milestone payments totaling up to $273 million, plus tiered royalties. This collaboration aims to address the significant cancer prevalence in China, particularly lung cancer, enhancing patient access to innovative therapies.
On May 28, 2021, Zai Lab Limited (NASDAQ: ZLAB) announced the dosing of the first patient in the registrational Phase 2 segment of the TRIDENT-1 study in China. This study evaluates repotrectinib for ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Repotrectinib aims to be a best-in-class treatment for these patients, showing promise due to its ability to address resistance to existing therapies. The FDA has granted various designations to repotrectinib, enhancing its development prospects in the oncology landscape.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has announced its participation in several virtual investor conferences in June 2021. The schedule includes a presentation at the Jefferies Healthcare Conference on June 2 at 10:00 a.m. EDT, a panel at the J.P. Morgan Global China Summit on June 3 at 10:45 a.m. HKT, and a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:50 a.m. EDT. Live webcasts will be available on the company’s website, along with archived replays for 90 days post-event.
Zai Lab Limited (NASDAQ: ZLAB) has announced the commencement of the METIS trial in Greater China, a Phase 3 pivotal study evaluating the efficacy of Tumor Treating Fields (TTFields) combined with radiosurgery for brain metastases from non-small cell lung cancer (NSCLC). This trial aims to enroll 270 patients, comparing the combination treatment against radiosurgery alone. With lung cancer being a leading cause of cancer incidence in China, this study addresses significant clinical needs. The primary endpoint is the time to cerebral progression, with secondary endpoints including overall survival.
Zai Lab Limited (NASDAQ: ZLAB) released its Q1 2021 financial results, reporting net product revenues of $20.1 million, up from $8.2 million year-over-year. Key highlights include the approval of QINLOCK for GIST in China and entering strategic collaborations enhancing its oncology and autoimmune portfolios. R&D expenses surged to $203.9 million due to significant upfront payments related to new partnerships. The company reported a net loss of $232.9 million or $2.64 per share, compared to a loss of $48.0 million or $0.66 per share in Q1 2020. Cash reserves stood at $1.01 billion as of March 31, 2021.
FAQ
What is the current stock price of Zai Lab American Depositary Shares (ZLAB)?
What is the market cap of Zai Lab American Depositary Shares (ZLAB)?
What does Zai Lab Limited specialize in?
When was Zai Lab Limited founded?
What are some key products in Zai Lab's pipeline?
How does Zai Lab Limited approach drug development?
What recent achievements has Zai Lab Limited made?
Who are the founders of Zai Lab Limited?
What partnerships has Zai Lab Limited established?
Where does Zai Lab Limited conduct clinical development?
Who backs Zai Lab Limited financially?
What is Zai Lab Limited's vision?
